About Ixcells Biotechnologies
Ixcells Biotechnologies is a Healthcare company based in San Diego (United States) founded in 2014. It offers patented stem cells and cell lines. Its website ixcellsbiotech.com draws about 14 thousand monthly visits. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its competitors include Avidity Biosciences, Sutro Biopharma and Antheia; 3 of its 3 listed competitors have raised funding.
Company details
Ixcells Biotechnologies was founded in 2014 in San Diego, United States, within the biotechnology sector. Patient-derived iPS cells are maintained for neuronal, cardiovascular, hematological diseases, and diabetes. Primary cell lines, cell culture reagents, iPS-derived cell lines, and RNAprotein extracts are offered. Customized cell-based assays and screening services are provided to support research operations.
- Headquarters San Diego, United States
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website ixcellsbiotech.com
- Social LinkedIn X Facebook
- Investors
Funding Insights of Ixcells Biotechnologies
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of Ixcells Biotechnologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2022 | Private Equity Round | – | – |
1 investors in total: 1 institutional.
Investors in Ixcells Biotechnologies
Ixcells Biotechnologies has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Great Point Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity firm focused on company buyouts | gppfunds.com | Greenwich, United States |
Investor details for Ixcells Biotechnologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Ixcells Biotechnologies
12 people are tracked at Ixcells Biotechnologies (5 in leadership, 7 in team).
| Name | Role | Group |
|---|---|---|
Jie Li | Senior Director (product) | Leadership |
Steve Smith | Chief Commercial Officer (cco) | Leadership |
Helge Bastian | Chief Executive Officer | Leadership |
Xinyu Kong | Director | Leadership |
Wayne Vaz | Vp, Corporate & Business Development | Leadership |
Andreea Manole | Senior Scientist Ii, Group Leader - Disease Modeling | Team |
Yunbo Li | Scientist Iii, Genome Editing & Assay Development | Team |
Bing Yan | Field Application Scientist | Team |
Alexander Ward | Senior Scientist II | Team |
Shuyang Zhang | Associate Scientist | Team |
Lilibeth Cervantes | Research Associate III | Team |
Joan Schein | Key Account Manager | Team |
Complete people profiles for Ixcells Biotechnologies
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Ixcells Biotechnologies
2 dated milestones of Ixcells Biotechnologies across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Ixcells Biotechnologies is founded.
- Funding First funding round.
Competitors of Ixcells Biotechnologies
Ixcells Biotechnologies has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Sutro Biopharma and Antheia.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. |
Detailed competitors of Ixcells Biotechnologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Ixcells Biotechnologies
The website of Ixcells Biotechnologies (ixcellsbiotech.com) receives about 14.2K visits a month.
- Monthly visits14.2K
▲ 5% vs previous month
Websites whose visitors overlap most with Ixcells Biotechnologies. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| teknova.com | 100% | 36.5K | #825,433 | View details | |
| zen-bio.com | 97% | 10.8K | #2,170,365 | View details | |
| stemcell.com | 90% | 262.4K | #179,047 | View details | |
| atcc.org | 90% | 408.3K | #141,426 | View details | |
| editco.bio | 84% | 18.3K | #1,232,653 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for Ixcells Biotechnologies
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Ixcells Biotechnologies (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ixcells Biotechnologies
Complete news archive for Ixcells Biotechnologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ixcells Biotechnologies
Ixcells Biotechnologies was founded in 2014 and raised its 1st funding round 8 years after it was founded.
Ixcells Biotechnologies is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Ixcells Biotechnologies was founded in 2014 in San Diego, United States, within the biotechnology sector. Patient-derived iPS cells are maintained for neuronal, cardiovascular, hematological diseases, and diabetes. Primary cell lines, cell culture reagents, iPS-derived cell lines, and RNAprotein extracts are offered. Customized cell-based assays and screening services are provided to support research operations.
Ixcells Biotechnologies's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.
Ixcells Biotechnologies has 1 investor. Key investors include Great Point Partners.